Remove Big Data Remove Development Remove Genome
article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

With approximately one third of all current FDA-approved drugs targeting GPCRs, Verily/Sosei Heptares are looking to expedite GPCR research within not only immunology, but also gastroenterology and immuno-oncology as well, and the latest data bodes well for future development of therapeutic options in these areas.

article thumbnail

Recognizing the Real People Behind the Big Data and Artificial Intelligence in Clinical Research

ACRP blog

If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “big data,” artificial intelligence (AI), and machine learning. Edited by Gary Cramer The post Recognizing the Real People Behind the Big Data and Artificial Intelligence in Clinical Research appeared first on ACRP.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

5th Microbiome Movement – Drug Development Summit Europe 2021

pharmaphorum

As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. The post 5th Microbiome Movement – Drug Development Summit Europe 2021 appeared first on.

article thumbnail

Integrated evidence generation 2.0: A strategy for every stakeholder

pharmaphorum

The advent of biologic therapies in the 1970s along with the decoding of the human genome in 2003 heralded an explosion in pharmaceutical innovation. This has led to an increase in products coming to market with single‑arm Phase 3 data and surrogate endpoints or Phase 2b data, with planned confirmatory data to be released in the future.

article thumbnail

Takeda, Daiichi-backed wearable study planned in Japan

pharmaphorum

The device will be worn by 2,000 people for a year, harvesting data on sleep status, heart rate, and activity levels, according to the study partners, which also include digital health and telemedicine firm MICIN and Tohoku University. ” The post Takeda, Daiichi-backed wearable study planned in Japan appeared first on.

article thumbnail

Digitalising drug discovery

pharmaphorum

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. . on Big data: astronomical or genomical? ,

article thumbnail

Bioinformatics Jobs: How to Succeed in This Competitive Space

XTalks

The Human Genome Project could not have succeeded without the use of bioinformatics. Since the conclusion of the project in 2003, bioinformatics tools have been used to identify genes and elucidate their function with the aim of developing gene-based strategies for disease prevention, diagnosis and treatment.